Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282093 | 0.96 | KMT2A (0.68) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL24608832 | 0.89 | MEN1 (0.52) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL8979409 | 0.89 | KMT2A (0.67) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL9999823 | 0.89 | KMT2A (0.61) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL9883387 | 0.87 | MEN1 (0.60) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL9883405 | 0.87 | MEN1 (0.60) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL31029916 | 0.86 | MEN1 (0.55) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL22548288 | 0.86 | MEN1 (0.55) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL9911140 | 0.85 | KMT2A (0.68) | KMT2AMEN1HPGDMTNR1AALDH1A1 | |
| SCHEMBL9911141 | 0.85 | KMT2A (0.68) | KMT2AMEN1HPGDMTNR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | ILYPSA, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | KMT2A 452/4885MEN1 2997/4885HPGD 673/4885 |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G5, PLA2G4A, PLA2G3 | KMT2A 1510/4885MEN1 1254/4885HPGD 3156/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | KMT2A 2990/4885MEN1 1896/4885HPGD 1675/4885 |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G1B, PLA2G2E, PLA2G4A | KMT2A 1409/4885MEN1 1413/4885HPGD 1461/4885 |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | PLA2G12A, PLA2G4A, PLA2G2E | KMT2A 1080/4885MEN1 1541/4885HPGD 482/4885 |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | PNLIP, PLA2G2E, PLA2G4B | KMT2A 3141/4885MEN1 2362/4885HPGD 1200/4885 |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | PNLIP, PLA2G1B, PLA2G4A | KMT2A 1112/4885MEN1 2733/4885HPGD 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.